Procept Biorobotics Corp

PRCT

28.740USD

+1.340+4.89%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Procept Biorobotics Corp's Score

Industry at a Glance

Industry Ranking

34 / 205

Overall Ranking

122 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Procept Biorobotics Corp Highlights

StrengthsRisks

PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 199.27% year-on-year.

Overvalued

The company’s latest PE is -18.74, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 59.67M shares, decreasing 3.70% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 1.34K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.66.

Analyst Rating

Based on 14 analysts

Buy

Current Rating

52.750

Target Price

+92.52%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Procept Biorobotics Corp is 8.11, ranking 57 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 83.33M, representing a year-over-year increase of 42.76%, while its net profit experienced a year-over-year increase of 2.08%.

Score

Industry at a Glance

Previous score

8.11

Change

0



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.98

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

7.60

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.67

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.32

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Procept Biorobotics Corp is 7.41, ranking 90 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -18.74, which is -43.01% below the recent high of -10.68 and -172.22% above the recent low of -51.02.

Score

Industry at a Glance

Previous score

7.41

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 34/205

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Procept Biorobotics Corp is 8.14, ranking 56 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 51.00, with a high of 75.00 and a low of 38.00.

Score

Industry at a Glance

Previous score

8.14

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Procept Biorobotics Corp is 6.85, ranking 79 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 33.69 and the support level at 25.23, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.42

Change

0.43

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Procept Biorobotics Corp is 10.00, ranking 1 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 106.79%, representing a quarter-over-quarter increase of 7.03%. The largest institutional shareholder is The Vanguard, holding a total of 5.19M shares, representing 9.29% of shares outstanding, with 0.43% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

7.89M

+2.45%

The Vanguard Group, Inc.

Star Investors

5.19M

-0.85%

BlackRock Institutional Trust Company, N.A.

3.73M

-0.10%

AllianceBernstein L.P.

3.42M

+58.55%

T. Rowe Price Investment Management, Inc.

2.05M

+34.35%

Westfield Capital Management Company, L.P.

1.97M

+23.26%

Mackenzie Investments

1.45M

+105.24%

Champlain Investment Partners, LLC

1.44M

+34.30%

Artisan Partners Limited Partnership

1.37M

+38.41%

State Street Investment Management (US)

1.32M

+4.38%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Procept Biorobotics Corp is 5.60, ranking 80 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.99. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Procept Biorobotics Corp

PRCT

7.70 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

LivaNova PLC

LIVN

8.61 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Cencora Inc

COR

8.47 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Becton Dickinson and Co

BDX

8.46 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

AxoGen Inc

AXGN

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Align Technology Inc

ALGN

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment